Skye Bioscience to Present at Investment and Medical Conferences

Skye Bioscience will participate in three investment conferences and two medical/scientific conferences, including a keynote panel and an oral presentation. The company will present data on its Phase 2a clinical trial for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, in obesity. Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors.

Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotech company focused on obesity and metabolic health disorders, has announced its participation in multiple upcoming conferences in September 2025. The company will present at three major investment conferences and two medical conferences, highlighting its progress in developing nimacimab, a negative allosteric modulating antibody for the treatment of metabolic disorders [1].

Investment Conferences

Skye will participate in the Cantor Global Healthcare Conference (Sept. 5), the H.C. Wainwright Global Investment Conference (Sept. 8), and the Morgan Stanley Global Healthcare Conference (Sept. 10). These conferences provide a platform for the company to engage with potential investors and share its strategic vision and progress in developing innovative therapies for metabolic health disorders.

Medical/Scientific Conferences

In addition to the investment conferences, Skye will present at two medical conferences: Obesity Science & Innovation in Boston and the EASD Annual Meeting in Vienna. At these conferences, the company will present data on nimacimab, its CB1 receptor antibody for the treatment of non-alcoholic fatty liver disease (MAFLD). The presentation will showcase the potential of nimacimab as a first-in-class therapeutic with clinical and commercial differentiation [1].

Clinical Trial Updates

Skye is currently conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab. The trial is assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). The company aims to demonstrate the superior safety and tolerability profile of nimacimab relative to other small molecule CB1 inhibitors, as well as its potential to change weight loss standards of care [1].

Safety and Tolerability

The company has emphasized the safety and tolerability of nimacimab in its clinical trials. Preliminary data suggest that nimacimab is well-tolerated, with a majority of treatment emergent adverse events (TEAEs) categorized as mild or moderate. The company will continue to monitor the safety profile of nimacimab as it progresses through clinical development [1].

Conference Schedule and Webcasts

Webcasts of the presentations will be accessible on Skye’s website. Investors and other stakeholders are encouraged to attend the conferences and engage with Skye's team to learn more about the company's progress and plans for the future [1].

References

[1] https://www.stocktitan.net/news/SKYE/skye-bioscience-to-participate-in-upcoming-investment-and-medical-ujxvza2853bs.html